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HSARPA has initiated a new Bioinformatics and Assay Development solicitation, 
BIAD2 (BAA 06-01), to address a number of technology gaps and requirements for 
biodetection (www.hsarpabaa.com).  This solicitation will leverage the vast research and 
development capabilities of the private sector and academia in order to meet the needs of 
HSARPA and Homeland Security. In order to meet these requirements, this solicitation 
will: 
· Develop and validate actionable assays for the public and private sector 
· Develop and validate new assays and novel assay methodologies to enhance 
existing detection systems and enable future detection platforms 
· Develop next generation assays which are robust against novel, emerging and 
engineered threats 
· Develop novel assays that detect low levels of ribonucleic acid (RNA)-based 
viral threats in complex backgrounds 
· Develop novel assays to characterize the viability, degree of virulence or 
toxicity, and countermeasure resistance of a biological agent 
· Develop new bioinformatics tools to support assay development and assay 
validation 
The Lawrence Livermore National Laboratory (LLNL) Bioassays and Signature Program 
(BSP) develops nationally-validated detection and identification assays to cover the full 
range of biological threat agents, starting from human, animal, and plant pathogens on the 
Select Agent list.  The assays that have been co-developed by the CDC and the BSP are 
used internationally and represent the gold standard for molecular detection of select 
agent pathogens for the public health community.  They are also used in the DHS 
environmental monitoring operations such as BioWatch and DHS National Security 
Special Events support.  These reagents have been used to process and analyze more than 
5 million samples and have delivered exceptional performance for the end users, with 
zero false positives since their deployment.  Currently, highly-multiplexed nucleic acid 
assays that represent the “next-generation” in BioWatch assays have been developed at 
LLNL and are in final evaluation at CDC.  LLNL is a full partner to the LRN network, as 
well as a formal LRN member, sanctioned to perform these diagnostics on field samples.  
The Program has assay extensive experience developing, testing, validating, deploying, 
and commercializing biodetection assays and instrumentation.  The following pages 
contain additional descriptions of our Program’s capabilities.  We have a demonstrated 
track record of established collaborations and look forward to partnering with offerers to 
the HSARPA BAA to continue to meet the national needs and requirements.  
For additional information, please contact Mary McBride at: mcbride2@llnl.gov.
The Chemical and Biological National Security Program at LLNL
The mission of the Chemical and Biological National Security Program, (CBNP) is to 
develop and field advanced strategies that dramatically improve the nation’s capabilities 
to prevent, prepare for, detect, and respond to terrorist use of chemical or biological 
warfare agents.  The science, technology and integrated systems we provide are informed 
by and developed with key partners and end-users. The key science and technology 
attributes of the program are centered around informatics, assays, and instrumentation for 
environmental and agricultural targets; biological knowledge discovery from disparate 
data sources; and a variety of response and operations efforts centered around forensics, 
restoration, and atmospheric modeling.  CBNP provides integrated access to a broad 
range of Laboratory skills and facilities, including:
· Special facilities in $5B infrastructure
o BSL-3 Pathogen Laboratory (activation Spring 2006)
o Fermentation Laboratory
o Forensic Science Center
o National Atmospheric Release Advisory Center (24x7)
o Biosecurity and Nanoscience Support Laboratory
o Micro Technology Center
o Center for Accelerator Mass Spectrometry
o Over 180 CBNP staff
o DHS Biodefense Knowledge Center (24x7)
The following information covers the specific capabilities and expertise:
· Bioassays and Signatures Program:  
o Assay Development Pipeline:  An Overview
o Sequencing Capabilities 
o BioInformatics
§ DNA Signature Development
§ Protein Signature Development
§ Broad Applications
o TaqMan Nucleic Acid Assay Development
o Multiplexed Nucleic Acid Assay Development
o Dissemination of Assay Products into User Communities
o Multiplexed Immunoassay Development
o Development of Protein Based Detection Reagents
o Functional Assays and Signatures
o High Throughput Laboratory
· BioInstrumentation Development Program 
o A Multiplexed Diagnostic Platform for use at Point-of-Care 
o An Advancement in Detection Systems – BioBriefcase
o High Throughput Rapid Viability Analysis
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Bioassays and Signatures Program: Assay Development Pipeline
The Bioassays and Signatures Program (BSP) at Lawrence Livermore National 
Laboratory (LLNL) have constructed a robust technical architecture (Figure 1) for the 
rapid development of highest-quality nucleic acid assays, tailored to end-users 
specifications.  This process is generic enough to be used for any signature type and any 
organism.  Our pipeline process has been used to provide high-confidence detection 
assays for many priority bioterrorism agents. The pipeline process begins with an 
analysis of all available genomic sequence information, which forms the basis for the 
development of signatures.  A signature is a region or set of regions on a chromosome 
that is unique to that organism.  The pipeline process of signature discovery and assay 
development utilizes a whole-genome approach where the entire genome is 
computationally examined to identify candidate regions that might be unique to the 
property or characteristic of interest. Knowledge about the function of the gene is not 
required, and many thousands of possible signatures can be rapidly generated to identify 
a few hundred of the most promising. Candidate signatures can be selected based on 
performance criteria for specific detection technologies.  Our nucleic acid assays employ 
PCR with primer pairs to 
generate the signature 
fragment(s) of interest.  Once 
candidate signatures have been 
identified, they are subjected to a 
computational screening and 
down-selection process.  This “in 
silico” screening method tests 
the candidate regions for 
uniqueness when compared to all 
the sequence data available.  The 
computational screening also 
ensures that the signature primer 
pairs are amenable to assay 
chemistry requirements and 
provides rapid, low-cost initial 
screening of  signatures.  The 
Figure 1.  The “tailored assay pipeline” process.  
primers that emerge from the computational screening and down-selection are then tested 
against an extensive panel of DNAs and cDNAs. The bench screening consists of a panel 
of 2,000 to 3,000 samples, representing a wide range of organisms and backgrounds.  
This bench screening ensures that the primers will detect the strain diversity of the 
pathogen but will not react with the nucleic acids of other organisms that could be present 
in a sample.  Primer pairs that successfully pass the wet chemistry screening criteria are 
advanced to the assay development stage. Assay development includes the optimization 
of extraction and detection protocols, so that the assays perform consistently to required 
specifications on the prototype equipment selected.  
Bioassays and Signatures Program: Sequencing Capabilities 
The assay development process sometimes begins with sequencing a particular isolate of 
interest.  LLNL is a founding partner to the Joint Genome Institute (JGI), who currently
performs standard Sanger sequencing at its Production Genomics Facility in Walnut 
Creek, California. The JGI is 
among the world leaders in 
whole-genome sequencing 
projects devoted to microbes and 
microbial communities, model 
system vertebrates, aquatic 
organisms, and plants. Since 1999 
they have produced ~ 110 billion 
quality bases of sequence with an 
average of 92% pass rates and 655 base pair read lengths.  The sequencing process for 
most genomes employs the whole-genome shotgun sequencing method to produce high-
quality draft sequence. The work begins with creation of 3-Kb, 8-Kb, and 40-Kb DNA 
libraries. Sequence is then obtained from both sides of the library insert, producing paired 
ends, typically resulting in approximately 8-9X depth. Reads are aligned by using various 
genome assemblers to produce the primary draft assembly, which consists of contigs 
linked into larger scaffolds by paired-end information. All genomes have at least a 
minimal automated annotation.  For additional information see the DOE JGI Website.
The BSP also has in-house sequencing capabilities. We have developed a shotgun 
sequencing protocol incorporating various aspects of technology developed by Dr. Joseph 
DeRisi at UCSF and the JGI that is capable of generating draft sequence with 4-10X 
coverage of most viral genomes within 4 days.  This process requires relatively pure viral 
nucleic acids.  We have demonstrated that this level of purification can be achieved by 
growing virus in a matrix relatively free of contaminating host nucleic acids, virion 
purification by sucrose-gradient ultracentrifugation, or by using special matrices for 
selective purification of replicative RNA from RNA viruses
The BSP, in collaboration with CDC, USAMRIID, and USDA and the University of 
Texas Medical Branch has sequenced the genomes of the following human and 
agricultural pathogens: Ebola (3 strains), Marburg (3 strains), Sabia, Lassa (7 strains), 
Guanarito, Machupo (3 strains), Junin (2 strains), Rift Valley Fever (7 strains), 
Bluetongue, Y. pestis (3 strains), VESV, and West Nile virus. All genome information 
has been deposited into public databases (e.g., GenBank ).
Through extensive collaborations, the BSP at LLNL has unique access to over 160+ 
pathogen genomes that are not currently available in public web sites. Although these 
genomes cannot be shared with others, the BSP signature generation process can utilize 
this information to ensure that the resulting signatures predict to perform properly with 
these data.
Bioassays and Signatures Program: BioInformatics – DNA Signature 
development
It is imperative to recognize the mutual interdependence of assays and bioinformatics:  
bioinformatics is the underpinning for assay development, providing the capacity for high 
throughput processing of whole genomic data to identify signatures for a variety of assay 
platforms. Assay development, in turn, provides feedback that drives computational 
enhancements and improvements. Within the BSP, bioinformatics and assays are 
intimately linked at each stage.   
Since 2000, the bioinformatics capabilities developed under the BSP have defined the 
state of the art in nucleic acid assay design, with a more recent extension to the design of 
protein reagents. Highly automated comparative genomics and proteomics analysis 
systems have isolated the best regions for both nucleic acid and protein signatures. 
The “KPATH” whole-genome comparative analysis software system (depicted below) 
first determines consensus (among one or more whole and/or draft genomes of the 
pathogen target) and then determines which portions of that consensus appear to be 
unique when compared to all other microbial genomes. Technically, a variety of anchor-
based or BLAST-based algorithms are used for consensus, depending on the target 
genomes available and the amount of rearrangement. A suffix-tree algorithm is used for 
efficient computation of apparent uniqueness. KPATH mines the consensus/uniqueness 
result for candidate signatures based on the format desired (TaqMan®, nested PCR, etc.), 
with the entire process taking under 2 hours for the largest bacterial pathogen targets. 
Additional electronic checking follows to look for inexact matches that might trigger 
false-positives, and signature candidates are correlated with available annotation to aid in 
priority selection.
The KPATH DNA Signatures Pipeline database enables signature development.  It is 
linked to provider and user entities, and supports views to details on taxonomy, signature
component, melting temperature, and GC content. It also provides in silico erosion and 
target verification with customizable report by date, recent update, and status (true 
positive, false positive, false negative, indeterminate).  The user can view details on 
percent identity, match layout, and highlight mismatches. Additional tools allow users to 
rapidly identify all predicted Taqman or primer pair targets from all sequenced nucleotide 
genomes or fragments including coordinates and gene product information. 
Signature and assay maintenance is vital, as new information about pathogens and near-
neighbors is being generated at ever-increasing rates. The KPATH system includes an 
automated “signature maintenance” process to accomplish this. New and updated 
microbial genomic sequence data is downloaded weekly from a variety of pertinent 
public sites. All fielded signatures for high-consequence pathogens are checked against 
this new data, with reports generated of potential false-positive and false-negative events. 
Over the past several years, this system has alerted us to several instances of both types 
of events, at which point we redesign the affected signatures to account for the new 
information.
Singleplex diagnostic signatures have been transformed into multiplexed assays, 
however, much work remains in this area, especially as new sequence data for divergent 
strains of some viral targets becomes available, and multiplexed and/or degenerate 
signatures are essential to detect all variant strains.  LLNL has developed software that 
effectively predicts the ability of arbitrary singleplex signatures to avoid cross-reactivity 
when multiplexed. Also, the standardized parameters of KPATH-derived signatures has 
fortuitously resulted in their working well together in multiplex format. 
To enable detection of diverse target sets, we have developed software that identifies the 
minimal number of signatures required to capture all desired targets.  This is aiding the 
development of reliable assays for influenza, arenaviruses, and other divergent RNA 
viruses. Results have been shared with various branches of CDC and other government 
agencies.
Bioassays and Signatures Program: BioInformatics- Protein Signature 
Development
Now, LLNL extends their nucleic acid based capabilities to proteins.  In FY2005 we 
achieved the ability to perform whole-proteome structural modeling. LLNL has built a 
protein structure modeling, classification, and analysis infrastructure, which has been 
applied to the identification of optimal protein features for targeting detection reagents.  
The Amino-acid to Tertiary Structure and Local-global Alignment systems provide a 
capability to rapidly create 3D models of proteins on a whole-proteome scale and to 
detect structurally conserved regions and other biologically significant fragments in 
protein structures.  This state-of-the-art protein modeling system is coupled with high-
throughput sequence- and structure-based analyses of conservation/uniqueness, and a 
fully automated protein annotation system, comprising LLNL’s protein signature 
evaluation (PSE) system. PSE is the only fully integrated, high-throughput informatics 
infrastructure that enables a rational approach to protein detection reagent design.  In 
addition, PSE is linked to LLNL’s virulence database, which provides sequences of
virulence proteins, antibiotic resistance genes, virulence islands, toxins, and select 
proteins that define pathogen-host interactions. 
We have applied this computational infrastructure to discover to protein signatures for 
Yersinia pestis, Bacillus anthracis, variola virus, foot and mouth disease virus, ricin, and 
botulinum toxin. 
Candidate signatures
are handed off to
chemists & biologists
Whole-proteome 
automated & empirical 
annotation
Proteome of fasta sequences
Sequence-based 
conserved & unique 
protein target regions
High-throughput 
protein 
modeling
Structure-based 
conservation/uniqueness
Map features 
to 3-D model
Evaluation and 
selection
Fig. 1.  High-throughput, computational protein signature evaluation system (PSE). 
Bioassays and Signatures Program: BioInformatics- Broad Applications
The next generation of signatures focuses on detection of what an organism can do, not 
only species or strain identification. Virulence and antibiotic resistance genes often have 
functional homologues in many species, for which the nucleotide and even the protein 
sequences diverge widely. We are using Hidden Markov Models to identify diverse 
members of known virulence gene families and designing microarray probes to detect all 
sequenced variants of these genes. A virulence chip will be useful to rapidly (~1 day) 
predict what pathways, drug resistances, and toxins may be available to an 
uncharacterized BT or emerging pathogen, in advance of full genomic sequence data or 
phenotypic characterization.
The bioinformatics team leads the development of databases containing potential 
signatures for detection of virulence, antibiotic resistance, and engineered pathogens and 
toxins; containing all publicly available, organized data for virulence proteins, toxins and 
viral host-pathogen interaction proteins, complete with navigation tools and blast 
interfaces.   
Support is also provided to DHS and other organizations for “scientific reachback” 
requests, often on short turn-around. Examples of this include a soybean rust analysis for 
the USDA, Yersinia analyses for USAMRIID/DHS, and Hepatitis-A assays for the FDA. 
A long and active collaboration with the CDC has supported their requests for help with 
poxvirus analyses and signatures (smallpox, vaccinia, monkeypox, cowpox, etc.), and 
similar analyses and signatures for SARS, influenza, brucella, Rift Valley Fever, Crimean 
Congo Hemorrhagic Fever, and many others.
Our computational tools have a direct impact on sequencing needs.  Our sequencing 
analysis capability directed the USDA to sequence both the Soybean Rust fungus, and its 
near neighbor P.meibomiae in order to create the best diagnostics. In addition, our 
signature design system can run on draft and incomplete sequences, so just the fosmid 
sequence libraries we needed instead of the complete genomes. Without these cost 
savings, this achievement would not have been possible.  
Several years of advanced bioinformatics research support by another federal agency has 
resulted in extensive SNP-based assays of published and unpublished data for organisms 
such as foot and mouth disease virus (FMDV) and the orthopox viruses (smallpox and 
related species.) These data could be readily transferred to different platforms suitable for 
forensic-level assays. We also have prototyped technologies suitable for massive-scale 
“forensic barcoding” of all select agents.
Finally, the LLNL bioinformatics team is involved in the design and use of the DHS 
Biodefense Knowledge Center (BKC), which uses advanced information fusion 
technology over a wide range of information to produce actionable intelligence.
Bioassays and Signatures: TaqMan® Nucleic Acid Assay Development
The BSP, in collaboration with the Centers for Disease Control and Prevention (CDC)  
has developed, tested, optimized and validated highly specific and sensitive TaqMan®-
based nucleic acid assays for selected Category A and B pathogens (Figure 1).  One set of 
these assays are deployed as part of BioWatch, and are available to the LRN for use 
within public health laboratories around the country and internationally.  A second set of 
assays, designed for detection of the highest priority environmental bacterial pathogens 
have been operationally deployed as part of the NNSA Biological Aerosol Sentry and 
Information System (BASIS) laboratory and are being moved into deeply multiplexed 
formats for detection on next generation instrumentation. The multiplexed assay that has 
been developed at LLNL is capable of simultaneous detection of 8 Category A and B 
pathogens using a 29-plex single-tube PCR with great sensitivity and selectivity. Many 
additional assays for other Category A, B, and C pathogens have been developed but 
have not yet been validated.  For example, with USAMRIID, the BSP has co-developed 
53 TaqMan®-based assays capable of specific and sensitive detection of a number of 
hemorrhagic fever viruses::  Ebola (17 signatures, providing genomic coverage across 
strains Reston, Sudan, and Zaire); Marburg (10 signatures capable of distinguishing 
between Raven and others strains of this virus); Rift Valley fever (8 signatures), Sabia (4 
signatures),  Lassa (7 signatures), Guanarito (4 signatures), Machupo (2 signatures), 
Junin (1 signature). 
Figure 1. Conventional TaqMan® PCR process is used to amplify target regions of the genome.  Typical 
data output is shown on the right.  
BSP support to the USDA has been ongoing for two years and these efforts have 
generated new diagnostics for use within the National Animal Health Laboratory 
Network (NAHLN) and the Plum Island Animal Disease Center (PIADC).  New 
diagnostic capabilities have been inserted into the NAHLN; these new capabilities 
include 34 individual TaqMan® assays. Twenty-one of these assays  have been 
incorporated into a single-tube RT-PCR multiplexed assay capable of distinguishing 
between foot-and-mouth pathogens virus (FMDV) and a panel of endemic domestic and 
foreign animal diseases that cause clinical signs in animals that are indistinguishable 
from FMDV.  
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Additional work is in progress to develop and validate highly comprehensive panels of 
signatures and assays for emerging pathogens, including avian influenza. We are 
working to develop nucleic acid assays for detection of influenza.  To date, 25 individual 
signatures have been developed and tested for the H1, H3. H5, and H7 influenza 
subtypes; additional work will provide signatures and assays for the remaining H 
subtypes.
Bioassays and Signatures:  Multiplexed Nucleic Acid Assay 
Development
Development of multiplexed assays (i.e., assays that can simultaneously test a single 
sample for multiple analytes) utilizes Luminex® bead-based liquid array technology.  
The liquid array is composed of polystyrene beads that can be individually tagged with 
specific antibodies, antigens, oligonucleotides, peptides, or other small molecules, 
enabling the development of assays that can be used for the detection of antigens, 
antibodies, nucleic acids, and enzymes (Figure 1).  The beads are imbedded with precise 
ratios of red and infrared fluorescent dyes, yielding an array of 100 different beads, each 
with a unique spectral “address.”  Beads with different tags can be mixed together, and 
up to 100 different pathogens can be tested accurately and concurrently.  
Figure 1.  (A) 100-plex Luminex liquid array generated by intercalating varying ratios of red and infrared 
dyes into polystyrene latex microspheres.  Each optically encoded bead has a unique spectral address. (B)
Beads are coated with capture oligos. The sequence of each capture oligo matches the PCR amplicon at a 
site between the two primer oligos just as TaqMan probes do (C) Standard biotin-labeled PCR products 
from a multiplex assay are allowed to hybridize to the bead set.  The fluorophore, R-phycoerythrin 
covalently coupled to strepavidin, is then introduced to and binds with the biotin-labeled PCR products.  
Beads are then individually interrogated in the flow cytometer.  A red laser excites the dye molecules inside 
the beads, and a green laser excites the fluorescent molecules bound to the bead surfaces.  
The BSP and CDC co-developed a deeply multiplexed multi-loci panel of nucleic acid 
assays (27-plex) for detection of 8 different biological threat agents; this panel of assays 
is under final evaluation by the CDC and will be validated in the LRN using a multi-
center collaborative study in March, 2006.  Validated assays will be transitioned to the 
private sector for commercialization and dissemination within the LRN.   These assays 
have also been developed and optimized in a TaqMan® format and transitioned to the 
CDC.  This multiplexed panel represents the next-generation of BioWatch assays:  the 
panel may eventually replace the TaqMan®-based primary and confirmatory detection 
assays currently used by the LRN BioWatch laboratories.   Using the multiplexed panel 
offers the BioWatch program 4 significant advantages over the current methods:  
1. Major reduction in reagent and labor costs.  Because the multiplexed assays are 
contained within a single tube and are performed simultaneously, the multiplexed 
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panel offers significantly enhanced detection capabilities with more than an 90% 
reduction in costs and significant savings in labor relative to the costs and time 
required to run each individual assay.  
2. The multiplexed panel comprises both the primary and confirmatory testing in a 
single test.  This will eliminate the time required to run the confirmation panel 
following a screen reactive; this will result in a confirmed positive hours sooner 
than under current protocols.  
3. The multiplexed nucleic acid panel employs the same detection/analysis 
equipment as the previously-validated multiplexed immunoassays:  therefore, the 
LRN labs will have the ability to test positive samples using an orthogonal 
detection method, and, the LRN labs will have toxin-detection capabilities, all 
available on the same instrument platform.  
4. These assays are compatible with high-throughput sample “surge” processing and 
analysis capacity robotics:  sample surge capability was fully-developed and 
tested in 2004, and will be piloted in the AgDDAP later this year.  Our sample 
processing capacity currently stands at about 4,000 samples per 10 hour shift, 
using a single line of equipment.  
Working with the USDA, the BSP has developed a deeply multiplexed (21-plex) assay 
for detection of 8 different foreign and domestic vesicular disease viruses.  These assays 
can be used to differentiate foot-and-mouth disease virus from other foreign and domestic 
vesicular disease viruses, where all the viruses cause clinical signs in animals that look 
alike. This panel was demonstrated in an inter-laboratory comparison study in the 
National Animal Health Laboratory Network (NAHLN); and will be evaluated with 
clinical diagnostic samples over the course of the next year.  The multiplexed assay panel 
will enter validation in FY2006, and LLNL is actively seeking partners for 
commercialization of this panel.  
Bioassays and Signatures:  Multiplexed Immunoassay Development 
Like the multiplexed nucleic acid panels described above, the BSP has employed the liquid 
array technology to develop deeply multiplexed panels of antibody based assays.  These 
antigen detection assays (immunoassays) employ a typical sandwich immunoassay format 
where antigen-specific capture antibodies are immobilized on the polystyrene beads, 
antigen is introduced and allowed to bind the beads, and the bound analyte is subsequently 
detected using secondary antibodies indirectly labeled with the fluorescent reporter, 
phycoerythrin (PE).  
A multiplexed panel of immunoassays for detection of biothreat agents has already been 
developed, validated and disseminated to the LRN; this panel is currently being used to 
augment the detection capabilities of BioWatch laboratories, by adding protein toxin 
detection capabilities.  This panel employs a 9-plex, although many additional assays 
have been developed since this panel was validated.  The BSP also retains a fully-
developed panel of multiplexed immunoassays for detection of simulants of biological 
threat agents.  These assays may find broad utility among the private sector or others who 
are developing biodetection instrumentation, where the integrated systems can be tested 
and optimized at the benchtop under Biosafety Level 1 or 2 conditions.  The stimulant 
panel enables high-quality testing and optimization, prior to testing of integrated systems 
involving BSL-3 level agents.  
Figure 1. A) 100-plex Luminex liquid array generated by intercalating varying ratios of red and 
infrared dyes into polystyrene latex microbeads. Each optically encoded bead has a unique 
spectral address. B) Beads are coated with capture antibodies specific for target antigens.  
After incubation with the antigens, secondary or detector antibodies are added, followed by 
addition of the fluorescent reporter, phycoerythrin to complete the “antigen sandwich”.  C) The 
beads are analyzed in the flow cytometer.  Beads are interrogated one at a time.  A red laser 
classifies the bead, identifying the bead type.  A green laser quantifies the assay on the bead 
surface – only those beads with a complete sandwich will fluoresce in the green, and the 
signal is a function of antigen concentration.
The BSP has developed a panel of multiplexed immunoassays for the detection of 
common respiratory pathogens, including influenza A and B, parainfluenza (types 1-3), 
RSV, and adenovirus.  The performance of this panel is under evaluation in a clinical 
study, an dearly results indicate sensitivity and specificity on par with other antibody-
based methods, but improvements are being made.  The BSP has also combined the 
respiratory panel (12-plex) with the validated biothreat agent panel (9-plex), and we have 
demonstrated that these two panels can be effectively combined with no loss in 
sensitivity or specificity to any individual assay.  Thus, the panel may have utility as a 
tool for surveillance or syndromic screening.  
The liquid array platform is exceptionally versatile and can be used to develop assays for 
a number of analytes.  In addition to the antigen capture assays, we have employed the 
converse, where the objective is to capture antibodies from solution.  Here, the beads are 
covalently coupled to protein, and used to capture antibodies specific to those proteins 
from solution.  In collaboration with the Canadian National Center for Foreign Animal 
Diseases, we have also developed a multiplexed protein-based assay for the 
differentiation of naturally-infected versus vaccinated animals (DIVA) for foot-and-
mouth disease.  These assays, also employing the liquid array technology, will be 
evaluated at the international level (OIE); if the assays meet evaluation criteria, they may 
help to resolve the issue of “vaccinate to live” vs. “vaccinate to kill” that has plagued the 
international FMDV community for more than 30 years.   Following validation, they will 
be transitioned to commercial diagnostic company.  
Bioassays and Signatures: Development of Protein Based Detection 
Reagents
Pathogen specific 3-dimensional protein features are a rich but largely untapped resource 
for affinity-based detection.  There has been a significant gap in the need for robust 
affinity reagents targeting pathogen protein signatures and the ability to produce these 
reagents.  Driven by these needs, LLNL BSP and others have established a “protein 
pipeline” reagent development effort.  The effort is based on identifying unique protein 
signatures with bioinformatic-driven computational modeling coupled with high 
efficiency reagent discovery capabilities based on reagent molecular platforms that are 
stable, modifiable and manufacturable.  The resulting computationally-focused high 
throughput reagent production is focused on generating sets of reagents that meet the 
high confidence levels required of the DHS end users and can be mass produced by a 
commercial vendor for pennies per reaction, upon demand, without relying on the use of 
animals or animal cell lines.
The Protein Pipeline project has 
identified unique protein 
signatures for five threat agents, 
Bacillus anthracis, Yersinia 
pestis, ricin, botulinum toxin, and 
Variola major., including 
multiple proteins from the whole 
organism threat agents. The 
methods used to generate these 
initial signature sets are general 
and are currently being applied to 
provide a steady-state of high-
value threat agent protein targets 
for reagent development.  The 
target sets can be used to inform 
and focus virtually any type of 
reagent discovery technology 
from combinatorial to rational 
design approaches. 
The Protein Pipeline project has 
focused on evaluating and 
employing complimentary reagent discovery technologies that together provide the 
highest chance of success to develop affinity reagents for virtually any pathogen protein 
target.  We have given high priority to technologies and molecular scaffolds that are 
robust, broadly applicable, and efficient.  Currently, potential protein affinity reagents 
have been identified, tested for binding to their protein target, and are currently being 
assessed for their ability to bind to the organism/ intact toxin. The initial evaluation of the 
first new protein-signature based detection reagents will be completed this spring.
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Figure X.  Bio-informatics are used to identify unique 
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Bioassays and Signatures: Functional Assays and Signatures
Post September 11th and the anthrax letters of Fall 2001, a shift in the direction of biodefense 
research has emerged with a new urgency for basic, discovery-driven science to provide 
novel solutions for biodefense preparedness. 
Basic science now has a clear role in supporting 
critical translational applications for Homeland 
Security. For example, host-pathogen 
interactions (Figure 1), which reflect the 
balance of host defenses and pathogen virulence 
mechanisms, contain key signatures or 
biomarkers that can be useful for unveiling 
virulence characteristics of pathogens, for 
detecting emergent or engineered agents, and 
for presymptomatic and presyndromic 
surveillance of infectious diseases. LLNL
groups focus on virulence mechanisms and 
host-pathogen interactions of Yersinia pestis
and Bacillus anthracis, the etiological agents of 
plague and anthrax, as well as other viral, 
microbial and toxin treats to the civilian, agricultural and food sectors. 
To address the need for orthogonal detection assays that can provide a level of functional 
or threat characterization, we have studied the proteomic, genomic and phenotypic traits 
within diverse microbial pathogens as well as proteomic, genomic, clinical, and 
immunohistopathological categorization of host response to diverse pathogens in rodent, 
cell, and whole blood models. From our studies, we are developing the basis for 
understanding pathogen diversity as it relates to effective detection. For example, 
different strains of Y. pestis and B. anthracis exhibit differential expression and metabolic 
phenotype that correlate with diversity in 
degree of virulence. This knowledge has 
identified candidate signatures for 
environmental monitoring. In the case of Y. 
pestis, it is known that alteration in 
physiological growth conditions from the 
temperature and calcium concentration 
found in the flea vector to that found in the 
mammalian host can induce virulence-
related expression in Y. pestis. In our 
studies, hundreds of proteins were 
differentially expressed between these 
growth conditions, and more notably 
between strains with known differences in 
virulence level (Figure 2). 
Figure 1. Host-pathogen interaction model 
of Yersinia pestis, depicting the Type III 
secretion mechanism. The interaction 
results in expression alterations within the 
pathogen and the host.
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Figure 2. Y. pestis proteomic map showing 
differentially expression detected by 
multiplexed fluorescent-based 2-D DIGE, 
identified by mass spectrometry.
Hierarchical clustering of proteomic data has enabled us to distinguish diverse pathogens 
based on rapid proteomic screening with comparison to a “Pathogen Signature Library”. For 
example, Figure 3 shows extended data analysis of differential expression within 4 diverse 
strains. From this data, it is possible to blindly classify unknown samples. Additional 
metabolic data from phenotypic arrays
provided evidence of biochemical 
pathways not indicated by the genome 
annotation or known biochemistry of 
Y. pestis. Further, we determined that 
phenotype could distinguish same 
species strains. Significant differences 
were detected between virulence 
inducing and vector-like growth 
conditions, and between same species 
strains with diverse virulence levels. 
We have also linked phenotype and 
functional metabolic pathway 
information to virulence factor 
expression and host response, 
providing a novel and unprecedented 
approach to threat characterization via 
a Systems Biology view.
Similarly, from host response characterization it is possible to distinguish exposure to 
multiple pathogens including: virulent from avirulent pathogens; Y. pestis from B. anthracis; 
near neighbors from each other; and, most strikingly, two virulent clinical isolates of Y. pestis 
with differences in virulence level. Distinct cytokine profiles shown in Figure 4 suggest that 
host-response signatures 
can be used for rapid 
rule-out diagnosis of 
anthrax, plague and 
other diseases. These 
results represent an 
obvious translational 
application to detection 
and surveillance with 
the added feature of 
threat assessment, such 
as would be needed 
following a pathogen 
release or an infectious
disease outbreak. From a detection perspective, our ultimate vision is that of a dipstick, 
mouthswab, or breathalyzer type of diagnostic for infectious diseases and pathogen 
identification/characterization based on signatures from host-pathogen interactions studies. 
Y. pestis NYC 
Y. pestis India
Y. enterocolitica 
Y. pseudotuberculosis 
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Figure 4. Heat map representation of cytokine expression in whole 
blood model following exposure to 7 pathogens.
Figure 3. Hierarchical clustering of Y. pestis 
proteomic data. Shown is data for 4 diverse strains 
grown under virulence-inducing and nonvirulent 
growth conditions. 318 proteins, from 1000s 
detected, could blindly classify the strains.
BioAssays and Signatures:  High Throughput Laboratory
The high-throughput laboratory (HTL) has been developed, maintained, and housed at 
LLNL and is a certified BioSafety Level Two Laboratory (BSL-2).  The HTL is a semi-
automated laboratory that uses robotic liquid handling platforms and 96-well assay 
technologies to rapidly process incoming samples.  We have demonstrated the ability to 
process more than 4,000 samples from end-to-end using just 2 technicians and a single 
line of equipment in a 10-hour shift.  Protocols have been developed such that the system 
can accept and process many different types of samples, including swabs, swipes, filters, 
and liquids, comprising different environmental sample matrices including soil, fresh 
water, and aerosols from a variety of filter matrices.  
The HTL has been successfully deployed many times, and can be operationally relocated 
and functioning within 24 hours.  This capability offers sample “surge” capacity that 
could be used to respond to outbreaks or suspected events of bioterrorism, or to 
support/augment existing laboratory capabilities such as those found within the public 
health community.  
Bioassays and Signatures:  Dissemination of Assay Products into User 
Communities
Over the past two years, the BSP has devised a well-developed strategy for testing, 
validation, commercialization, and final dissemination of TaqMan and Multiplexed assay 
products into user communities.  We have developed well organized and detailed Assay 
Report Cards that capture in seven main tabs all of the information necessary to 
determine the capabilities and limitations of any nucleic acid assay.  These tabs include:
1.  Bioinformatics (all target and near-neighbor sequences used to generate signatures; 
type of target [DNA/RNA; virus, bacterium, fungus]; genome size)
2.  Signature summary (sequences of all primers and probes used in the final assay; 
GC content; length; melting temperature; location on genome; target gene 
description)
3.  Level of discrimination (eg. Species, strain, subspecies, etc.)
4.  List of all samples use for screening (including all soils, zoos, microbes, aerosols,
targets, and near-neighbors)
5.  Erosion report (detailed info. on potential cross-reactivities)
6.  TaqMan report (including Limit of Detection on multiple targets)
7.  Multiplex assay report (number of signatures included in Multiplex assay, cross-
reactivities, limits of detection, etc.)
These report cards have gone a long way to bridge the gaps that exist between research 
and translation of assays into the hands of the user community. The BSP at LLNL 
comprises unparalleled assay development capabilities, a unique and comprehensive 
diagnostics testbed that enables assays and/or diagnostic platforms to be thoroughly 
evaluated by directly comparing performance to other state-of-the-art 
assays/instrumentation, and a training and technology transfer program that has placed 
assays, instrumentation, and training directly into the hands of our partners at the 
CDC/LRN and the United States Department of Agriculture National Animal Health 
Laboratory Network [USDA/NAHLN].
BioInstrumentation Development Program: Bioassays and Signatures: A
Multiplexed Diagnostic Platform for use at Point-of-Care
The preceding pages have provided a description of our multiplexed assay development 
efforts, using both nucleic acid (PCR) and protein (immunoassay) methods.  We have also 
developed similar panels for the detection of common respiratory pathogens; these panels 
are finding utility in the clinical setting, especially at point-of-care.   The nucleic acid-
based assay panel is under development, but currently provides for rapid, sensitive, and 
specific detection of up to eight different respiratory pathogens simultaneously from a 
single sample. Our multiplexed assays have been developed for FluIDx, an integrated 
system designed for use at point-of-care. FluIDx is capable of sample preparation and 
processing (e.g., nucleic acid extraction), performing highly multiplexed real-time PCR 
nucleic-acid based assays, data analysis and reporting, and system decontamination 
between samples, where all functions are completely automated. FluIDx currently employs 
an 18-plex panel, comprising assays for 8 respiratory pathogens (Influenza Virus A and B 
subtypes, Parainfluenza Virus Types 1-3, Respiratory Syncytial Virus, Adenovirus, and 
SARS) where each agent is represented by multiple loci, and 5 unique internal controls.  
Results on a patient sample can be provided in about 3 hours.  
The performance of FluIDx will be benchmarked in a year-long pilot, beginning October, 
2005.  An instrument has been deployed into the hospital emergency room at the University 
of California Davis Medical Center in Sacramento, CA. The pilot will enable training, 
demonstration, and evaluation of the system by hospital personnel  The prototype  system 
is depicted in the photograph in Figure 1a; shown in Figure 1b is an artist’s rendering of the 
instrument repackaged into a clinically-relevant outer housing. 
(A) (
B)
Figure 1.  (A) Photograph of the prototype device, showing monitor, fluidics manifold and Luminex 50 
detection system.  (B) FluID device with housing.
BioInstrumentation Development Program: An Advancement in 
Detection Systems - BioBriefcase
The CBNP and Sandia National Laboratory have collaborated to produce the 
BioBriefcase, a briefcase-sized, multiplex, autonomous, broad-spectrum bioagent 
detector.  This instrument monitors the environment and provide “detect-to- treat” 
capability for civilian applications, relevant to the Bioagent Autonomous Networked 
Detectors (BAND) provided by DHS.  We have developed a concept that uses 
microfluidics and chip-based modules for performing sample preparation and analysis.  
This device employs three separate and orthogonal analysis methods – PCR, 
immunoassay, and protein signature – to provide two analysis methods each for the 
detection of bacteria and viruses (PCR and immunoassay) and toxins (immunoassay and 
protein signature).  All three of the analysis modes employ capillary electrophoresis with 
laser-induced fluorescence detection.  The BioBriefcase features multiplex capability, 
dramatically reduced reagent consumption, decreased cost, and decreased size, while 
maintaining or improving sensitivity and response time compared to currently available 
technologies.  The Bio Briefcase was successfully field tested with simulants in early 
FY06.  
BioInstrumentation Development Program: High Throughput Rapid 
Viability Analysis
Current innovative biodetection technologies are often limited by issues of front-end 
sample processing, and are challenged to efficiently transfer pathogen cells or spores 
from environmental or clinical samples to a form compatible with the small volumes 
required for nucleic acid or immuno-based assays. The method limit of detection is 
negatively impacted by losses during this transfer process as well as by the assay’s 
inability to measure pathogen in the entire sample. In addition, methods typically do not 
distinguish viable and potentially infectious pathogen from dead pathogen, important 
information for determining the risk of exposure. Current methods for extraction and 
analysis of viable pathogens are labor and time-intensive, with low throughput, and have 
relatively high detection limits. Although traditional real-time PCR assays provide rapid, 
specific and sensitive detection of pathogens, they fall short of determining viability.  
Recently, a Rapid Viability (RV)-PCR method based on a significant change in real-time 
PCR response after incubation of the sample has been developed and tested on several 
biothreat (BT) agents at LLNL.  The method was able to detect growth of B. anthracis
within 4 hours from a complex environmental sample (HEPA vacuum sock filled with 
debris from a mailroom) containing contamination below detectible levels (40 
spores/mL). Substantial time reductions were achievable for viability determination for 
other BT organisms (Table 1). 
Table 1.  Comparison of Rapid Viability PCR with conventional culture-based analysisa.
Criterion Rapid Viability PCRb Conventional Assayc
Analysis time for:
 B. anthracis
 Y. pestis
Brucella sp.
F. tularensis
4-6 hr
6-8 hr
6-8 hr
8-10 hr
2-4 days
3-5 days
5-7 days
7 days
Sample processing 
throughput/day
200 dirty wipes/4-6 hr for
1 person and 1 robot
30 wipes/8 hr for B. a., 
2 people
Detection limit 1-10 spores per wipe NA
a  The cost/analysis for RV-PCR is approximately one-half that of the conventional assay due to decreased labor 
requirements.  b PCR analysis at time 0 was below detection.  The change in PCR response at the endpoint 
showed an increase of at least 2 logs in cell population; c  NA = data not available.
In parallel, high throughput sample processing protocols that are compatible with PCR 
analysis have been developed, allowing processing of hundreds of samples (e.g., wipes, 
filters, filtrates) in short turn around times (4-6 hr) using commercially available robotics. 
In field-testing, the protocols could accommodate a large amount of background debris 
without decreasing throughput and detection limits were consistently £10 spores. Testing 
also showed that 10 live B. anthracis surrogate spores could be detected in a background 
or 106 chlorine dioxide-killed spores. Both automated and field-deployable protocols 
significantly reduce the amount of manual sample handling g, therefore reducing the risk 
of exposure to personnel.  Other features include the ability to archive the culture and 
lysates for additional PCR and biochemical analyses and validation. The protocols are 
compatible with all relevant sample types including fluids, filters, wipes, swabs, and 
vacuum socks.  Air samples from wet collection methods such as cyclone samplers 
reported to maintain viability of collected microorganisms could easily be incorporated 
into sample processing protocols. Modifications are being made to high throughput 
protocols to accommodate vegetative cell targets, maintaining cell viability throughout 
the process allowing the technology to be widely applied to bacterial pathogens. 
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